Table 1. Patient characteristics.
|
Polish cohort |
|
|
Swedish cohort |
|
|
|||
|---|---|---|---|---|---|---|---|---|
| |
Case |
|
Controls |
|
Case |
|
Controls |
|
| n | % | n | % | n | % | n | % | |
|
T | ||||||||
| 0 | 0 | 0.0 | 1 | 0.5 | — | — | — | — |
| 1 | 31 | 32.0 | 100 | 51.5 | — | — | — | — |
| 2 | 41 | 42.3 | 60 | 30.9 | — | — | — | — |
| 3 |
6 |
6.2 |
2 |
1.0 |
— |
— |
— |
— |
|
N | ||||||||
| 0 | 35 | 36.1 | 94 | 48.5 | — | — | — | — |
| 1 | 14 | 14.4 | 26 | 13.4 | — | — | — | — |
| 2 | 16 | 16.5 | 26 | 13.4 | — | — | — | — |
| 3 |
13 |
13.4 |
17 |
8.8 |
— |
— |
— |
— |
|
HER2 | ||||||||
| − | 44 | 45.4 | 100 | 51.5 | 158 | 83.2 | 161 | 84.7 |
|
+ |
15 |
15.5 |
51 |
26.3 |
18 |
9.5 |
13 |
6.8 |
|
PR | ||||||||
| − | 42 | 43.3 | 93 | 47.9 | 108 | 56.8 | 60 | 31.6 |
|
+ |
30 |
30.9 |
65 |
33.5 |
73 |
38.4 |
127 |
66.8 |
|
ER | ||||||||
| − | 35 | 36.1 | 77 | 39.7 | 79 | 41.6 | 41 | 21.6 |
|
+ |
37 |
38.1 |
81 |
41.8 |
103 |
54.2 |
147 |
77.4 |
|
BRCA1 | ||||||||
| Normal | 25 | 25.8 | 68 | 35.1 | — | — | — | — |
| Mutant |
13 |
13.4 |
51 |
26.3 |
— |
— |
— |
— |
|
Familial | ||||||||
| No | 24 | 24.7 | 82 | 42.3 | — | — | — | — |
| Yes |
15 |
15.5 |
59 |
30.4 |
— |
— |
— |
— |
|
Hormonal therapy | ||||||||
| Yes |
— |
— |
— |
— |
53 |
27.9 |
48 |
25.3 |
|
Adjuvant radiotherapy | ||||||||
| Yes | — | — | — | — | 101 | 53.2 | 116 | 61.1 |
Abbreviations: ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; PR=progesterone receptor.
The patient population is described according to the clinical variables, separately for the Polish and Swedish cohorts. In cases where the percentage numbers do not add up to 100, the information was available only for a fraction of patients.